Heterozygous germline mutation in the BRCA1 gene confers a 60% lifetime risk of breast or ovarian cancer, whereas BRCA2 mutations are associated with a risk of breast or ovarian cancer of 55% and 15%, respectively [19]. This evidence concerns the gene BRCA2 and ovarian cancer.